{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:20:23Z","timestamp":1790680823807,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Classical myeloproliferative neoplasms (MPNs) are characterized by the proliferation of myeloid cells and the risk of transformation into myelofibrosis or acute myeloid leukemia (AML) and <jats:italic>TP53<\/jats:italic> mutations in MPN patients are linked to AML. However, JAK2V617F has been reported to impact the <jats:italic>TP53<\/jats:italic> response to DNA damage, suggesting potential overlapping role of TP53 inactivation in MPN. We established a mouse model showing that JAK2V617F\/Vav-Cre\/Trp53<jats:sup>\u2212\/\u2212<\/jats:sup> mice displayed a similar phenotype to JAK2V617F\/Vav-Cre mice, but their proliferation was outcompeted in competitive grafts. RNA-Seq revealed that half of the genes affected by JAK2V617F were affected by p53-inactivation, including the interferon pathway. To validate this finding, mice were repopulated with a mixture of wild-type and JAK2V617F (or JAK2V617F\/Vav-Cre\/Trp53<jats:sup>\u2212\/\u2212<\/jats:sup>) cells and treated with pegylated interferon\u03b1. JAK2V617F-reconstituted mice entered complete hematological remission, while JAK2V617F\/Vav-Cre \/Trp53<jats:sup>\u2212\/\u2212<\/jats:sup>-reconstituted mice did not, confirming that <jats:italic>p53<\/jats:italic> loss induced interferon-\u03b1 resistance. KEGG and Gene Ontology analyses of common deregulated genes showed that these genes were mainly implicated in cytokine response, proliferation, and leukemia evolution, illustrating that in this mouse model, the development of MPN is not affected by TP53 inactivation. Taken together, our results show that many genetic modifications induced by JAK2V617F are influenced by TP53, the MPN phenotype may not be. <jats:italic>Trp53<\/jats:italic> loss alone is insufficient to induce rapid leukemic transformation in steady-state hematopoiesis in JAK2V617F MPN, and <jats:italic>Trp53<\/jats:italic> loss may contribute to interferon resistance in MPN.<\/jats:p>","DOI":"10.1038\/s41408-023-00969-6","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T07:02:52Z","timestamp":1704351772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9408-5663","authenticated-orcid":false,"given":"Panhong","family":"Gou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duanya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravanan","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Lauret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5553-462X","authenticated-orcid":false,"given":"Nabih","family":"Maslah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Parietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Meignin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-3905","authenticated-orcid":false,"given":"Bruno","family":"Cassinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1817-2236","authenticated-orcid":false,"given":"Stephane","family":"Giraudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"969_CR1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PeterJ Campbell","year":"2006","unstructured":"Campbell PeterJ. ARG. The myeloproliferative disorders. N Engl J Med. 2006;355:2452\u201366.","journal-title":"N Engl J Med"},{"key":"969_CR2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"V Ugo","year":"2005","unstructured":"Ugo V, James C, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"969_CR3","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"969_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJoanna Baxter","year":"2005","unstructured":"Baxter EJoanna, Scott LindaM, Campbell PeterJ, East Clare, Fourouclas Nasios, Swanton Soheila, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"969_CR5","doi-asserted-by":"publisher","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788\u201392.","journal-title":"J Biol Chem"},{"key":"969_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RossL Levine","year":"2005","unstructured":"Levine RossL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"969_CR7","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/onc.2011.313","volume":"31","author":"M Nakatake","year":"2012","unstructured":"Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E, et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31:1323\u201333.","journal-title":"Oncogene"},{"key":"969_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","volume":"124","author":"M Lu","year":"2014","unstructured":"Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014;124:771\u20139.","journal-title":"Blood"},{"key":"969_CR9","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","volume":"120","author":"M Lu","year":"2012","unstructured":"Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-\u03b1 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120:3098\u2013105.","journal-title":"Blood"},{"key":"969_CR10","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.hoc.2012.07.005","volume":"26","author":"AS Harutyunyan","year":"2012","unstructured":"Harutyunyan AS, Kralovics R. Role of germline genetic factors in MPN pathogenesis. Hematol Oncol Clin North Am. 2012;26:1037\u201351.","journal-title":"Hematol Oncol Clin North Am"},{"key":"969_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000204873","volume":"85","author":"F Cervantes","year":"1991","unstructured":"Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85:124\u20137.","journal-title":"Acta Haematol"},{"key":"969_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJMc1012718","volume":"364","author":"A Harutyunyan","year":"2011","unstructured":"Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364:488\u201390.","journal-title":"N Engl J Med"},{"key":"969_CR13","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"969_CR14","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","volume":"123","author":"N Bhagwat","year":"2014","unstructured":"Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014;123:2075\u201383.","journal-title":"Blood"},{"key":"969_CR15","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1038\/onc.2016.478","volume":"36","author":"T Tsuruta-Kishino","year":"2017","unstructured":"Tsuruta-Kishino T, et al. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. Oncogene. 2017;36:3300\u201311.","journal-title":"Oncogene"},{"key":"969_CR16","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1182\/blood.2021014465","volume":"139","author":"B Li","year":"2022","unstructured":"Li B, An W, Wang H, Baslan T, Mowla S, Krishnan A, et al. BMP2\/SMAD pathway activation in JAK2\/p53-mutant megakaryocyte\/erythroid progenitors promotes leukemic transformation. Blood. 2022;139:3630\u201346.","journal-title":"Blood"},{"key":"969_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/348747a0","volume":"348","author":"S Srivastava","year":"1990","unstructured":"Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747\u20139.","journal-title":"Nature"},{"key":"969_CR18","doi-asserted-by":"publisher","first-page":"610820.","DOI":"10.3389\/fonc.2020.610820","volume":"10","author":"M Molica","year":"2021","unstructured":"Molica M, Mazzone C, Niscola P, de Fabritiis P. TP53 mutations in acute myeloid leukemia: still a daunting challenge? Front Oncol. 2021;10:610820.","journal-title":"Front Oncol"},{"key":"969_CR19","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220\u20138.","journal-title":"Blood"},{"key":"969_CR20","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","volume":"115","author":"PA Beer","year":"2010","unstructured":"Beer PA, Delhommeau F, LeCou\u00e9dic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891\u2013900.","journal-title":"Blood"},{"key":"969_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/leu.2017.230","volume":"32","author":"B Kubesova","year":"2018","unstructured":"Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, et al. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018;32:450\u201361.","journal-title":"Leukemia"},{"key":"969_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.hemonc.2016.04.003","volume":"9","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther. 2016;9:89\u201395.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"969_CR23","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","volume":"122","author":"S Hasan","year":"2013","unstructured":"Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. Blood [Internet]. 2013;122:1464\u201377. https:\/\/doi.org\/10.1182\/blood-2013-04-498956.","journal-title":"Blood [Internet]"},{"key":"969_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.V91.2.419","volume":"91","author":"S Ogilvy","year":"1998","unstructured":"Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, Adams JM. Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998;91:419\u201330.","journal-title":"Blood"},{"key":"969_CR25","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.V94.6.1855","volume":"94","author":"S Ogilvy","year":"1999","unstructured":"Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood. 1999;94:1855\u201363.","journal-title":"Blood"},{"key":"969_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/gene.10023","volume":"32","author":"DR Shimshek","year":"2002","unstructured":"Shimshek DR, et al. Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis. 2002;32:19\u201326.","journal-title":"Genesis"},{"key":"969_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/356215a0","volume":"356","author":"M Learning","year":"1992","unstructured":"Learning M, Cookbook R. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215\u201321.","journal-title":"Nature"},{"key":"969_CR28","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","volume":"55","author":"A Rodriguez-Meira","year":"2023","unstructured":"Rodriguez-Meira A, Norfo R, Wen S, Ch\u00e9deville AL, Rahman H, O\u2019Sullivan J, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023;55:1531\u201341.","journal-title":"Nat Genet"},{"key":"969_CR29","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","volume":"121","author":"A Mullally","year":"2013","unstructured":"Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera. Blood. 2013;121:3692\u2013702.","journal-title":"Blood"},{"key":"969_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.430","volume":"7","author":"Z Ren","year":"2016","unstructured":"Ren Z, Aerts JL, Vandenplas H, Wang JA, Gorbenko O, Chen JP, et al. Phosphorylated STAT5 regulates p53 expression via BRCA1\/BARD1-NPM1 and MDM2. Cell Death Dis. 2016;7:e2560.","journal-title":"Cell Death Dis"},{"key":"969_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/onc.2014.60","volume":"34","author":"M Girardot","year":"2015","unstructured":"Girardot M, Pecquet C, Chachoua I, van Hees J, Guibert S, Ferrant A, et al. Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene. 2015;34:1323\u201332.","journal-title":"Oncogene"},{"key":"969_CR32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1126\/science.272.5262.719","volume":"272","author":"YE Chin","year":"1996","unstructured":"Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1\/CIP1 mediated by STAT1. Science. 1996;272:719\u201322.","journal-title":"Science"},{"key":"969_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.0959-9673.2003.00363.x","volume":"84","author":"A Stephanou","year":"2003","unstructured":"Stephanou A, Latchman DS. STAT-1: a novel regulator of apoptosis. Int J Exp Pathol. 2003;84:239\u201344.","journal-title":"Int J Exp Pathol"},{"key":"969_CR34","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","volume":"108","author":"JJ Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037\u201340.","journal-title":"Blood"},{"key":"969_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/leu.2015.326","volume":"30","author":"JJ Kiladjian","year":"2016","unstructured":"Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776\u201381.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00969-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T07:03:22Z","timestamp":1704351802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00969-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00969-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}